世界の三重特異性抗体市場(~2024):市場機会・臨床試験インサイト

◆英語タイトル:Global Trispecific Antibodies Market Opportunity and Clinical Trials Insight 2024
◆商品コード:KUIK21FB006
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年12月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥273,600見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥410,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の三重特異性抗体市場について調査・分析を行い、イントロダクション、臨床レベル研究による癌症例、モノクローナル抗体&二重特異性抗体薬物市場の課題を克服した三重特異性癌抗体薬物療法市場、三重特異性癌抗体療法による癌の研究開発部門を改善するための新しい経路構築、進行中研究&三重特異性癌抗体医薬品市場のコラボによる世界市場の影響、臨床パイプライン、課題、将来見通し、競争状況などを掲載しています。
・イントロダクション
・臨床レベル研究による癌症例
・モノクローナル抗体&二重特異性抗体薬物市場の課題を克服した三重特異性癌抗体薬物療法市場
・三重特異性癌抗体療法による癌の研究開発部門を改善するための新しい経路構築
・進行中研究&三重特異性癌抗体医薬品市場のコラボによる世界市場の影響
・臨床パイプライン
・課題
・将来見通し
・競争状況
【レポートの概要】

“Global Trispecific Antibodies Market Opportunity and Clinical Trials Insight 2024″ Report Highlights:

Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion
Trispecific Antibodies In Clinical Trials: > 8 Antibodies
Highest Phase of Development: Phase I/II
Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies
Numab Therapeutics Dominating the Trispecific Development Pipeline
Prevention and Second Line Therapy Key Focus of Development of Trispecific Antibodies

Trispecific cancer antibody therapy market at an early phase of development has crossed a long path to get recognized and appreciated as one of the most innovative and important breakthrough and achievement ever done in the complete cancer therapeutics sector. The development of antibody capable of targeting three different targets with the help of recombinant biotechnology is leading to the further explication of the market that monoclonal and bispecific antibodies were once performing at a very accelerated rate. Overall scientific information about the antibody targeting and how increasing the number of targeting molecules can increase the efficacy of the treatment triggered the researchers to develop a market that is inclined towards more specificity and eventually a steady decline in the global mortality rate due to cancer.

Trispecific cancer antibody therapy involves innovative approach of targeting three different epitopes present on the cancer cells which has apparently led to the acceptance of the therapy at clinical level for further evaluation. The unique mechanism of action of the therapy is also estimated to follow the path which will be driven by robust sales of the future drugs under the therapy. Some of the driving parameters that are associated with the overall market are: increase in the number of cancer cases, increase in cancer mortality rate, increased awareness of the antibody therapy applications and huge impact of the overall immunotherapy on the cancer patients.

The current details of the therapy at clinical level is reflecting the true performance where the therapy is anticipated to witness a remarkable growth with respect to revenue and size as the number of clinical research studies, investments and strong clinical base are coupled with the therapy from the starting. As per analysis conducted, it is estimated that the potential applications of tri-specific cancer antibody therapy is bound to sweep away the market trends and opportunities of all the other traditional therapies, once the therapy gets accepted for commercial use by the patients.

The global trispecific cancer antibody therapy market is believed to be growing with novel innovative trends and opportunities as assessed for other important immunotherapies due to the presence of latest methodologies in the industry. The applications range within the therapy is also believed to get enhanced through the means of extensive research and development environment developed in course of time for therapies such as tri-specific cancer antibody therapy. The therapy from the starting is associated with strategic alliances which are leading the therapy towards more specificity towards different varieties of cancers such as multiple myeloma, breast cancer, non-small cell lung cancer and many more. It is estimate that the therapy with the aid of growing tons of trends and opportunities will significantly grow and observe a speedy expansion in the next few years.

【レポートの目次】

Introduction to Global Trispecific Cancer Antibody Drug Market
1.1 Trispecific Cancer Antibody Mechanism of Action Against Cancer Cells
1.2 History of the Development of Trispecific Cancer Antibody Drug Development

Cancer Cases Engaging More Potential Trispecific Cancer Research Studies at Clinical Level
2.1 Trispecific Cancer Antibody Drug Therapy Market Beneficial for all Cancer Types
2.2 Potential Trispecific Cancer Antibody Therapy for Non-Small Cell Lung Cancer
2.3 Potential Trispecific Cancer Antibody Drug Therapy for the Treatment of Breast
Cancer
2.4 Potential Trispecific Cancer Antibody Therapy Market for Prostate Cancer
2.5 Potential Trispecific Cancer Antibody Therapy Market for Rest of the Cancer
Types
2.6 Trispecific Cancer Antibody Drug Immunotherapy Market as a Saviour for
Increasing Prevalence of Cancer Cases
2.7 Trispecific Antibody Immunotherapy Market Clinical Experience

Clinical Insights for Current Trispecific Cancer Antibody Drug Therapy Market
3.1 Importance of Clinical Research Studies for the Overall Development of
Trispecific Cancer Antibody Drug Therapy Market
3.2 Research Clinical Insights for Trispecific Cancer Antibody Drug Therapy against
Multiple Myeloma

Trispecific Cancer Antibody Drug Therapy Market Overcoming the Challenges for Monoclonal Antibody and Bispecific Antibody Drug Market
4.1 Trispecific Cancer Antibody Drug Therapy Market an Enhanced Version of
Monoclonal Antibody Therapy Market
4.1.1 Trispecific Cancer Antibody Drug Therapy Vs. General Monoclonal Antibody
Drug Class
4.1.2 Construction Benefits of Using Trispecific Cancer Antibody Drug Therapy Over
Monoclonal Antibodies
4.2 Trispecific Cancer Antibody Drug Therapy in Overcoming Bispecific Cancer
Antibody Drug Therapy Challenges

Tri-Specific Natural Killer Cell Nanoengagers to Address Cancer Therapeutic Indication

Forging Novel Pathways for Improving Research and Development Sector for Cancer by Trispecific Cancer Antibody Therapy
6.1 Trispecific Cancer Antibody Drug Therapy Market Research and Development Sector
Promoting Current Cancer Therapy Market
6.2 Novel Trispecific Cancer Antibody Therapy Drugs to Boost Chemotherapy Cancer
Market
6.3 Novel Trispecific Cancer Antibody Drug Market Boosting the Future Radiation
Therapy Market
6.4 Novel Trispecific Cancer Antibody Drug Market Boosting Other Available Cancer
Therapies Market

Global Market Implications for Ongoing Research Studies and Collaborations for Trispecific Cancer Antibody Drug Market
7.1 Numab and Vasella Therapeutics to Collaborate for PD-L1x4-1BBxHSA Trispecific
ND021 Candidate in the Cancer Patients
7.2 GTB-3550 Trispecific Recombinant Fusion Protein Development by GT Biopharma
7.3 Sanofi to Target Bi-specifcic and Multi-Specific Antibodies for Overall Development
of Cancer Pharmaceutical Industry
7.4 Sunshine Pharmaceuticals and Numab Therapeutics to Undergo Partnership for the
Development of Multi-Specific Cancer Antibody Drugs for Cancer Patients
7.5 SAR 441236 Trispecific Cancer Antibody Drug Development by Brigham Health
Hospital
7.6 Numab Therapeutics Evaluation of NM21-1480 Trispecific Cancer Antibody in the
Solid Cancer Patients

Global Trispecific Antibodies Clinical Pipeline Overview
8.1 By Country
8.2 By Indication
8.3 By Organization
8.4 By Patient Segment

Global Trispecific Antibodies Pipeline Clinical Insight By Company, Indication and Phase
9.1 Reserach
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II

Insight for Driving Factors and Challenges for the Trispecific Cancer Antibody Drug Market
10.1 Driving Parameters for Trispecific Cancer Antibody Drug Market
10.2 Challenge Observed for the Current Trispecific Cancer Antibody Drug Therapy
Market

Future Directions for Trispecific Cancer Antibody Drug Therapy Market at Global Level

Competitive Landscape
12.1 AbbVie
12.2 Affimed
12.3 Biotheus
12.4 Harpoon Therapeutics
12.5 Macrogenics
12.6 Numab
12.7 Sanofi
12.8 Sichuan Baili Pharmaceuticals



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の三重特異性抗体市場(~2024):市場機会・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆